Dr. Reddy’s Omeprazole Case: Is Pediatric Exclusivity Extension Of Patent?
Executive Summary
Dr. Reddy's legal rationale for why it should get 180-day exclusivity for 40 mg omeprazole could include an argument that pediatric exclusivity be treated as an extension of the drug's patent life
You may also be interested in...
Dr. Reddy’s Omeprazole Case Vs. FDA Challenges Patent-By-Patent Exclusivity
Dr. Reddy's omeprazole case against FDA challenges the agency's decision to award exclusivity on a patent-by-patent basis
Dr. Reddy’s Omeprazole Case Vs. FDA Challenges Patent-By-Patent Exclusivity
Dr. Reddy's omeprazole case against FDA challenges the agency's decision to award exclusivity on a patent-by-patent basis
“Shared” Generic Exclusivity In Multi-Patent Cases Speeds Launch – FDA
Providing shared exclusivity to generic applicants ensures faster access to market for generics, FDA said in explaining its shift from a "patent by patent" approach to 180-day exclusivity